Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00042055
Status:
COMPLETED
Last Update Posted:
2011-10-17
First Post:
2002-07-22
Brief Title:
CP-461 for the Treatment of Crohns Disease
Sponsor:
Astellas Pharma Inc
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
A Phase II Pilot Study of CP-461 in the Treatment of Moderately to Severely Active Crohns Disease
Status:
COMPLETED
Status Verified Date:
2011-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with moderately to severely active Crohns disease will be treated with oral CP-461 200 mg 2 x 100 mg capsules twice-daily for 8 weeks
The purpose of this study is to see if CP-461 improves the symptoms of Crohns disease andor the patients quality of life Patients safety will be monitored throughout the study
The purpose of this study is to see if CP-461 improves the symptoms of Crohns disease andor the patients quality of life Patients safety will be monitored throughout the study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None